

INTRODUCING

Pathogen Reduced Plasma, Cryoprecipitate Reduced

produced from the

INTERCEPT[®] Blood System for Cryoprecipitation

INTERCEPT® Pathogen Reduced Plasma, Cryoprecipitate Reduced

- For **transfusion or therapeutic plasma exchange (TPE)** in patients with **thrombotic thrombocytopenic purpura (TTP)**¹
- **Pathogen reduced, blood component**
- Serves as an **source of plasma proteins with reduced levels of fibrinogen, factor XIII, vWF, and factor VIII** compared to unfractionated FFP



* INTERCEPT® Pathogen Reduced Plasma, Cryoprecipitate Reduced has not been evaluated in a clinical setting
FFP = fresh frozen plasma



Availability

- Provided in single-use containers
- Received frozen with up to 12 months shelf life
- May be stored at 1-6° C for up to 5 days without relabeling
- Provided as 240-295 mL units


Catalog #	Description
PCR	Pooled Plasma, Cryo Reduced, Psoralen Treated

Pathogen Reduction

- INTERCEPT® Pathogen Reduced Plasma, Cryoprecipitate Reduced is produced from pathogen reduced plasma by the INTERCEPT Blood System for Plasma Pathogen Reduction System
- Broad spectrum transfusion transmitted infection† risk reduction, including viruses, bacteria, and other pathogens^{1,2}



INTERCEPT® Blood System for Plasma Mechanism of Action



Upon UVA illumination, amotosalen cross-links nucleic acids to block replication and inactivates pathogens

INTERCEPT® treated plasma has 20 years of clinical and post-market surveillance experience

†There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and *Bacillus cereus* spores have demonstrated resistance to the INTERCEPT® process. For a full list of pathogens, please refer to package inserts.

Intended Use

- Transfusion or therapeutic plasma exchange (TPE) in patients with thrombotic thrombocytopenic purpura (TTP)
- Provide coagulation factors, except fibrinogen, factor VIII, factor XIII, and von Willebrand factor (vWF), for transfusion support of patients with appropriate clinical indications



Contraindications

Contraindicated for preparation of blood components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens.

Contraindicated for preparation of blood components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

Pathogen Reduced Plasma, Cryoprecipitate Reduced should not be used for replacement of coagulation factors known to be depleted in this product: fibrinogen, factor VIII, vWF and factor XIII.

Warnings and Precautions

Only the INTERCEPT® Blood System for Cryoprecipitation is approved for use to produce Pathogen Reduced Plasma, Cryoprecipitate Reduced.

References

1. INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Plasma, Cryoprecipitate Reduced [Package Insert]. Concord, CA. Cerus Corporation. January 20, 2021.
2. INTERCEPT Blood System for Plasma [Package Insert]. Concord, CA, Cerus Corporation. May 1, 2020.



GLOBAL HEADQUARTERS | 1220 Concord Avenue | Concord, CA US 94520 | 855.835.3523
www.cerus.com | www.intercept-cryoprecipitation.com

Rx only.